FIELD: chemistry.
SUBSTANCE: invention relates to fluorine-substituted cyclic amino compound of general formula I or a pharmaceutically acceptable salt thereof. Compounds of formula I have acetylcholinesterase inhibitor properties. In formula I
general formula Im is an integer equal to 1; n is an integer equal to 0; X is (CH2)p or CO, where p is an integer equal to 1 or 2; R1 is an unsubstituted C3-C10 cycloalkyl or substituted or unsubstituted phenyl; substitute(s) R1 is (are) 1, 2, 3, 4 or 5 identical or different substitutes independently selected from a group consisting of halogen, C1-C6 alkyl, halogen-substituted C1-C6 alkyl, C1-C6 alkoxycarbonyl, halogen-substituted C1-C6 alkoxy, cyano, nitro, phenyl; or two adjacent phenyl substitutes and carbon atom(s) of phenyl together form a 5-member heterocyclic radical, containing 2 heteroatoms selected from O; each of R2 and R3 is independently selected from a group consisting of hydrogen, carboxyl, C1-C4 alkoxycarbonyl and C1-C4 alkyl; or R2 and R3 together form C1-C4 alkylidene; R4 represents 2 substitutes selected from a group consisting of halogen, C1-C6 alkoxy, halogen-substituted C1-C6 alkoxy and -O[(CH2)qO]rR5, where R5 is selected from a group consisting of C1-C6 alkyl; wherein q equals 1; r is equal to 1; said halogen is F, Cl, Br or I. Invention also relates to a method of producing a fluorine-substituted cyclic amino compound, a pharmaceutical composition, acetylcholinesterase inhibitor and use of fluorine-substituted cyclic amino compound to prepare drugs for treating or preventing acetylcholinesterase-associated nervous system diseases.
EFFECT: technical result is obtaining novel compounds of fluorine-substituted cyclic amino compound of general formula I, having acetylcholinesterase inhibitor properties.
11 cl, 4 tbl, 92 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SULFONYL UREA AND RELATED COMPOUNDS AND USE THEREOF | 2016 |
|
RU2739356C2 |
| SULPHONYLUREAS AND RELATED COMPOUNDS AND THEIR USE | 2016 |
|
RU2795512C2 |
| NOVEL DERIVATIVES HAVING FRAGMENT OF 2,3-DIHYDRO-1H-INDENE OR 2,3-DIHYDROBENZOFURAN, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEREOF | 2020 |
|
RU2826099C1 |
| VIRAL REPLICATION INHIBITORS, METHOD FOR PRODUCTION THEREOF AND THERAPEUTIC APPLICATIONS THEREOF | 2014 |
|
RU2678575C2 |
| 5-AROMATIC ALKYNYL-SUBSTITUTED BENZAMIDE COMPOUND AND METHOD FOR PRODUCTION THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 2016 |
|
RU2695371C2 |
| PYRIMIDO[5,4-B]INDOLIZINE OR PYRIMIDO[5,4-B]PYRROLIZINE COMPOUND, METHOD FOR PRODUCTION THEREOF AND USE THEREOF | 2017 |
|
RU2721774C1 |
| PHARMACEUTICAL USE OF KETOAMIDE-BASED COMPOUND | 2021 |
|
RU2819346C1 |
| 1,3-DIOXOINDENE DERIVATIVES, THEREOF PHARMACEUTICALLY ACCEPTABLE SALT, METHOD OF OBTAINING THEREOF AND PHARMACEUTICAL ANTIVIRAL COMPOSITION, CONTAINING IT AS ACTIVE INGREDIENT | 2012 |
|
RU2566761C2 |
| SULPHONAMIDE COMPOUNDS AND USE THEREOF AS STAT5 INHIBITORS | 2015 |
|
RU2707094C2 |
| ANTIFIBROUS PYRIDINONES | 2015 |
|
RU2692485C2 |
